

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[HA562 trade name]*

Efavirenz, emtricitabine and tenofovir disoproxil fumarate 600mg/200mg/300mg
film-coated tablets

[HA562 trade name], manufactured at Macleods Pharmaceuticals Limited, Kachigam, Daman, India, was included in the WHO list of prequalified medicinal products for the treatment of HIV/AIDS on 17 November 2014.

[HA562 trade name] is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and adolescents weighing at least 35 kg. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredients of [HA562 trade name] are efavirenz, emtricitabine and tenofovir disoproxil.

The efficacy and safety of efavirenz, emtricitabine and tenofovir disoproxil are well established based on extensive clinical experience in the treatment of HIV/AIDS.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of efavirenz, emtricitabine and tenofovir disoproxil in HIV/AIDS, the team of assessors advised that [HA562 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [HA562 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [HA562 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Initial acceptance	Date	Outcome
Status on PQ list	17 November 2014	Listed
Pharmaceutical quality	05 May 2014	MR
Bioequivalence	28 April 2014	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	28 May 2014	MR
API	28 August 2014	
FPP	24 May 2014	MR
GCP/GLP (re-)inspection	12 February 2013	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

Requalification	20 October 2022.
------------------------	------------------